Location Matters: Belly Fat Compared to Overall Body Fat More Strongly Linked to Psoriasis Risk

Researchers have found that central body fat, especially around the abdomen, is more strongly linked to psoriasis risk than total body fat, particularly in women. This link between central fat and psoriasis remained consistent regardless of genetic predisposition, indicating that abdominal fat is an independent risk factor. The studyopens in new tab/window in the Journal of Investigative Dermatologyopens in new tab/window, published by Elsevier, provides insights that could help improve early risk prediction and guide personalized prevention strategies.

Psoriasis is a chronic inflammatory skin condition that can have a significant impact on quality of life. Many individuals with psoriasis also have elevated levels of body fat. While it is well established that increasing levels of body fat raise the risk of developing psoriasis, the impact of specific fat distribution and genetics remains unclear.

Researchers of the current study analyzed data from over 330,000 participants with White British ancestry in the UK Biobank, including more than 9,000 people with psoriasis. They examined 25 different measures of body fat using both traditional methods and advanced imaging techniques, assessing how each was associated with psoriasis.

Lead investigator Ravi Ramessur, MD, St John’s Institute of Dermatology, King’s College London, explains, "Our research shows that where fat is stored in the body matters when it comes to psoriasis risk. Central fat — especially around the waist — seems to play a key role. This has important implications for how we identify individuals who may be more likely to develop psoriasis or experience more severe disease, and how we approach prevention and treatment strategies."

Catherine H. Smith, MD, also at St John’s Institute of Dermatology, King’s College London, and senior author adds, “As rates of obesity continue to rise globally, understanding how different patterns of body fat influence chronic inflammatory conditions such as psoriasis is important. Our findings suggest that central body fat contributes to psoriasis risk irrespective of genetic predisposition and reinforces the importance of measuring waist circumference and pro-active healthy weight strategies in psoriasis care.”

Because this study only included individuals of White British ancestry from the UK Biobank, the generalizability of these findings to more diverse populations may be limited. Future studies incorporating datasets with dermatologist-confirmed diagnoses and broader ethnic representation will be important to further validate these associations and refine risk stratification approaches.

Dr. Ramessur notes, "We were surprised by how consistently strong the association was across different central fat measures and how much stronger the effect was in women. The observed links between central body fat and psoriasis suggest that there may be underlying biological mechanisms contributing to the disease that are not yet fully understood and which warrant further investigation."

In an accompanying editorialopens in new tab/window Joel M. Gelfand, MD, MSCE, FAAD, Department of Dermatology and Center for Clinical Sciences in Dermatology, University of Pennsylvania Perelman School of Medicine, points to the potential of incretin therapy for psoriatic disease. Incretins are gut-derived hormones, principally glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP), that regulate glucose, digestion, and appetite, and are approved for treatment of diabetes, obesity, and obesity-associated obstructive sleep apnea.

Dr. Gelfand comments, “The strong relationship between psoriasis and obesity and the emerging promise of glucagon-like peptide-1 receptor agonists (GLP1RA) for reducing psoriasis morbidity is a call to action for large scale clinical trials of GLP1RA monotherapy for treatment of psoriasis. Our current paradigm of just focusing on the skin and joint manifestations when treating psoriasis is outdated in the context of our evolving understanding of the tight relationship of psoriasis, obesity, and cardiometabolic disease.“

Notes for editors

The article is “Investigating the Genetic Basis of the Influence of Adiposity on Psoriasis: A Cross-Sectional Study in a Large United Kingdom Population–Based Biobank,” by Ravi Ramessur, Jake Saklatvala, Mari Løset, Laurent F. Thomas, Ashley Budu-Aggrey, Satveer K. Mahil, Jonathan N. Barker, Nick Dand, Michael A. Simpson, and Catherine H. Smith (https://doi-org.ucc.idm.oclc.org/10.1016/j.jid.2025.03.024opens in new tab/window). The article is openly available for 60 days at https://www.jidonline.org/article/S0022-202X(25)00391-4/fulltextopens in new tab/window.

The editorial is “The Visceral Relationship of Psoriasis and Obesity,” by Joel. M. Gelfand (https://doi-org.ucc.idm.oclc.org/10.1016/j.jid.2025.04.013opens in new tab/window). The editorial is openly available for 60 days at https://www.jidonline.org/article/S0022-202X(25)00456-2/fulltextopens in new tab/window.

They appear online in the Journal of Investigative Dermatology, published by Elsevier.

The full text of the articles is also available to credentialed journalists upon request; contact Eileen Leahy at +1 732 406 1313 or [email protected]opens in new tab/window. Journalists wishing to interview the authors should contact Bethan Warman, Senior Communications Officer, King’s College London, at [email protected]opens in new tab/window. Joel M. Gelfand, MD, MSCE, FAAD, may be reached for comment at [email protected]opens in new tab/window.

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 821511 (BIOMAP). The JU receives support from the European Union’s Horizon 2020 research and innovation program and EFPIA. This publication reflects only the authors’ views, and the JU is not responsible for any use that may be made of the information it contains.

This research was supported by the King’s Health Partners Centre for Translational Medicine. The views expressed are those of the authors and not necessarily those of King’s Health Partners. This study was also supported by the Psoriasis Association, UK.

About the Journal of Investigative Dermatology

The Journal of Investigative Dermatologyopens in new tab/window (JID) is the official journal of the Society of Investigative Dermatology and the European Society for Dermatological Research. JID publishes high impact reports describing original research related to all aspects of cutaneous biology and skin diseases. Descriptions of important findings that result from basic, translational, or clinical research are published. Clinical research can include, but is not limited to, interventional trials, genetics studies, epidemiology, and health services research. www.jidonline.orgopens in new tab/window

엘스비어 소개

엘스비어는 첨단 정보와 의사결정 지원 분야의 글로벌 선도 기업으로 100년 넘게 과학과 헬스케어의 발전을 지원하며 인류 진보에 기여해 왔습니다. 우리는 170개국 이상에서 학술 및 기업 연구 커뮤니티, 의사, 간호사, 미래의 의료 전문가와 교육자들을 지원합니다. 근거에 기반한 신뢰할 수 있는 과학·의학 콘텐츠와 최첨단 AI 기술을 결합해 중요한 통찰과 혁신적인 솔루션을 제공해, 의미있는 성과를 이루도록 돕고 있습니다. 또한 다양성과 지속 가능성을 제품과 기업 문화 전반에 내재화하며, 우리가 속한 커뮤니티와 협력합니다. 엘스비어 재단opens in new tab/window은 전 세계에서 연구와 보건 파트너십을 지원합니다.

엘스비어는 전문가 및 기업 고객에게 정보 기반의 분석과 의사결정 도구를 제공하는 글로벌 기업 RELXopens in new tab/window의 일원입니다. 자세한 내용은 www.elsevier.com에서 확인할 수 있으며, 소셜미디어 @elsevierconnect를 통해 최신 소식을 받아보실 수 있습니다.